

January 18, 2021

JIG-SAW INC.

Masunaru Yamakawa

President & Representative Director, CEO

(Stock Code: 3914 TSE Mothers)

JIG-SAW receives U.S. patent approval for software-based cell control technology (eyesight regeneration project: NEW-VISION technology) in field of regenerative medicine

JIG-SAW INC. (HQ: Tokyo, hereinafter “JIG-SAW”) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office with respect to the patent for software-based cell control technology (eyesight regeneration project: NEW-VISION technology) in the field of regenerative medicine. Since the patent will now come into effect via the prescribed procedure, JIG-SAW is pleased to announce details of its invention as shown below.

Title of invention	Head Mounted Type Video Presenting Device Including Visible Light Wavelength Converting Unit
Patent application number	16/471,394
Filing date	June 19, 2019

The invention is a smart glasses type video presenting device incorporating JIG-SAW's proprietary visible light wavelength converting software and the aim of the invention is to regenerate the eyesight of persons who have completely lost their sight. To begin with, JIG-SAW plans to conduct clinical investigation of the device in conjunction with clinical trials of gene therapeutic agents used to treat diseases such as retinitis pigmentosa (*1). This is a groundbreaking initiative which aims to regenerate the eyesight of those who have lost their sight due to retinal disease by using JIG-SAW's proprietary wavelength converting software with an algorithm to control the color signals sent to cells. JIG-SAW aims to combine the invention with gene therapeutic agents to enable those who have lost their eyesight due to a retinal disease to discern scenes and other persons' faces and to read and write.

For further details about this initiative, please refer to JIG-SAW's NEW-VISION website.

<https://www.newvision-prj.com/>

JIG-SAW continues to push ahead with completely unique regenerative medicine initiatives with a view to registering patents in countries all around the world.

The impact of this patent approval on JIG-SAW's consolidated business results is currently being examined carefully and JIG-SAW will promptly disclose any information which needs to be made public in the future.

*1 Retinitis pigmentosa is a retinal degenerative disease induced by an abnormal change in genes. It typically manifests in symptoms such as progressive night blindness, constriction of the visual field and visual loss and leads to a loss of color vision and eventual blindness.